Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer

Jorianne Boers; Carolina P Schröder; Geke A P Hospers; Erik F J de Vries; Andor W J M Glaudemans

doi:10.1097/RLU.0000000000003382

Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer

Jorianne Boers^*, Carolina P Schröder, Geke A P Hospers, Erik F J de Vries, Andor W J M Glaudemans

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

4 Citations (Scopus)

77 Downloads (Pure)

Abstract

We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16 alpha-[F-18]fluoro-17 beta-estradiol ([F-18]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [F-18]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [F-18]-FDG PET because of physiological [F-18]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [F-18]-FES PET imaging. [F-18]-FES PET could be used to prove the presence of ER-positive metastases in the brain.

Original language	English
Pages (from-to)	e165-e167
Number of pages	3
Journal	Clinical Nuclear Medicine
Volume	46
Issue number	3
Early online date	10-Nov-2020
DOIs	https://doi.org/10.1097/RLU.0000000000003382
Publication status	Published - Mar-2021

Keywords

[F-18]-FES PET
brain metastases
breast cancer
estrogen receptor

Access to Document

10.1097/RLU.0000000000003382

Detection_of_Dural_Metastases_Before_the_Onset_of.96373Final publisher's version, 296 KBLicence: Taverne

Handle.net

Persistent link

Cite this

Boers, J., Schröder, C. P., Hospers, G. A. P., de Vries, E. F. J., & Glaudemans, A. W. J. M. (2021). Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer. Clinical Nuclear Medicine, 46(3), e165-e167. Advance online publication. https://doi.org/10.1097/RLU.0000000000003382

@article{6ce7ec7f0c8a467a9982d459fc9dd872,

title = "Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer",

abstract = "We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16 alpha-[F-18]fluoro-17 beta-estradiol ([F-18]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [F-18]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [F-18]-FDG PET because of physiological [F-18]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [F-18]-FES PET imaging. [F-18]-FES PET could be used to prove the presence of ER-positive metastases in the brain.",

keywords = "[F-18]-FES PET, brain metastases, breast cancer, estrogen receptor",

author = "Jorianne Boers and Schr{\"o}der, {Carolina P} and Hospers, {Geke A P} and {de Vries}, {Erik F J} and Glaudemans, {Andor W J M}",

year = "2021",

month = mar,

doi = "10.1097/RLU.0000000000003382",

language = "English",

volume = "46",

pages = "e165--e167",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

number = "3",

}

Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer. / Boers, Jorianne ; Schröder, Carolina P ; Hospers, Geke A P et al.
In: Clinical Nuclear Medicine, Vol. 46, No. 3, 03.2021, p. e165-e167.

Research output: Contribution to journal › Editorial › Academic › peer-review

TY - JOUR

T1 - Detection of Dural Metastases Before the Onset of Clinical Symptoms by 16 alpha-[F-18]Fluoro-17 beta-Estradiol PET in a Patient With Estrogen Receptor-Positive Breast Cancer

AU - Boers, Jorianne

AU - Schröder, Carolina P

AU - Hospers, Geke A P

AU - de Vries, Erik F J

AU - Glaudemans, Andor W J M

PY - 2021/3

Y1 - 2021/3

N2 - We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16 alpha-[F-18]fluoro-17 beta-estradiol ([F-18]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [F-18]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [F-18]-FDG PET because of physiological [F-18]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [F-18]-FES PET imaging. [F-18]-FES PET could be used to prove the presence of ER-positive metastases in the brain.

AB - We offer an illustrative case about estrogen receptor (ER) imaging (also known as 16 alpha-[F-18]fluoro-17 beta-estradiol ([F-18]-FES) PET) and the detection of metastatic lesions in the dural region. We present a case of a woman with ER-positive metastatic breast cancer and high [F-18]-FES uptake in the dural region on PET imaging, without associated clinical symptoms. These lesions were missed on [F-18]-FDG PET because of physiological [F-18]-FDG uptake in the brain. This case highlighted some difficulties in the interpretation of imaging of brain metastases and demonstrated the added value of [F-18]-FES PET imaging. [F-18]-FES PET could be used to prove the presence of ER-positive metastases in the brain.

KW - [F-18]-FES PET

KW - brain metastases

KW - breast cancer

KW - estrogen receptor

U2 - 10.1097/RLU.0000000000003382

DO - 10.1097/RLU.0000000000003382

M3 - Editorial

C2 - 33181752

SN - 0363-9762

VL - 46

SP - e165-e167

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 3

ER -